Clinical Trial Update: Bortezomib in Rejection of Kidney Transplants [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib for chronic antibody-mediated rejection in kidney transplants has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Transplant Rejection
• Kidney Transplant Rejection

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Chronic Antibody-mediated Transplant Rejection | Phase 2 | Status: COMPLETED